Neurocrine Biosciences, Inc.

NASDAQ: NBIX    
Share price (5/7/24): $143.19    
Market cap (5/7/24): $14.4 billion
Search in Documents
Key Exhibits
External Links
5 Neurocrine Biosciences, Inc. Expert Interviews, now on BamSEC.
 Powered by Tegus.

Material Contracts Filter

EX-10.2
from 10-Q 4 pages Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Option Grant Notice
12/34/56
EX-10.1
from 10-Q 5 pages Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Rsu Award Grant Notice
12/34/56
EX-10.1
from 10-Q 24 pages Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Adopted by the Compensation Committee: March 16, 2020 Approved by the Stockholders: May 19, 2020 Amended and Restated by the Compensation Committee: March 14, 2022 Approved by the Stockholders: May 18, 2022 Amended by the Compensation Committee: March 24, 2023 Approved by the Stockholders: May 17, 2023 Termination Date: March 15, 2030
12/34/56
EX-10.4
from 10-Q 7 pages Material contract
12/34/56
EX-10.3
from 10-Q 10 pages Material contract
12/34/56
EX-10.2
from 10-Q 25 pages Material contract
12/34/56
EX-10.1
from 10-Q 6 pages Threatened Breach of Any Such Provisions by Executive, in Addition to Any Other Relief (Including Damage) Available to the Company Under This Agreement or Under Law. (B) Exclusive. Both Parties Agree That the Remedy Specified in Section 7.9(a) Above Is Not Exclusive of Any Other Remedy for the Breach by Executive of the Tenns Hereof. 7.10 Counterparts. This Agreement May Be Executed in One or More Counterparts, All of Which Taken Together Shall Constitute One and the Same Agreement. Executed by the Parties as Follows: Executive By: Date: 10/28/2014 Page 17of20 109912199 V2 Neurocrine Biosciences, Inc. By: Date: 10/27/2014 /S/ Darin Lippoldt /S/ Kevin C. Gorman
12/34/56
EX-10.3
from 10-Q 10 pages Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan Adopted by the Board of Directors: February 6, 2018 Approved by the Stockholders: May 24, 2018 Amended and Restated by the Compensation Committee: March 14, 2022 Approved by the Stockholders: May 18, 2022
12/34/56
EX-10.2
from 10-Q 32 pages Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Adopted by the Compensation Committee: March 16, 2020 Approved by the Stockholders: May 19, 2020 Amended and Restated by the Compensation Committee: March 14, 2022 Approved by the Stockholders: May 18, 2022 Termination Date: March 15, 2030
12/34/56
EX-10.1
from 10-Q 18 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 86 pages Material contract
12/34/56
EX-10.17
from 10-K 9 pages Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Option Grant Notice
12/34/56
EX-10.10
from 10-K 62 pages Dated 22 November 2021 Heptares Therapeutics Limited (1) and Neurocrine Biosciences, Inc. (2) Collaboration and License Agreement Contents
12/34/56
EX-10.4
from 10-Q 103 pages License Agreement
12/34/56
EX-10.3
from 10-Q 56 pages Collaboration and License Agreement
12/34/56
EX-10.2
from 10-Q 2 pages First Amendment (“First Amendment”) to the Collaboration and License Agreement Dated as of June 15, 2010 (The “Collaboration Agreement”) by and Between Abbott International Luxembourg S.À R.L., a Corporation Organized and Existing Under the Laws of Luxembourg, With Offices at 26, Boulevard Royal, L-2449 Luxembourg (“Abbott”) and Neurocrine Biosciences, Inc., a Corporation Organized and Existing Under the Laws of Delaware With Offices at 12780 El Camino Real, San Diego, California 92130 (“Neurocrine”) Is Made This Thirty-First Day of August, 2011 (“First Amendment Effective Date”)
12/34/56
EX-10.1
from 10-Q 60 pages Collaboration Agreement Dated June 15, 2010 by and Between Abbott International Luxembourg S.À R.L. and Neurocrine Biosciences, Inc
12/34/56
EX-10.3
from 10-Q 106 pages Exclusive License Agreement by and Between Takeda Pharmaceutical Company Limited and Neurocrine Biosciences, Inc. June 12, 2020
12/34/56
EX-10.2
from 10-Q 11 pages Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Option Grant Notice
12/34/56
EX-10.1
from 10-Q 37 pages Neurocrine Biosciences, Inc. 2020 Equity Incentive Plan Adopted by the Compensation Committee: March 16, 2020 Approved by the Stockholders: May 19, 2020 Termination Date: March 15, 2030
12/34/56